# Assessment of Physical Functioning and Handling of Spiolto® Respimat® in Patients With Chronic Obstructive Pulmonary Disease (COPD) Requiring Long-acting Dual Bronchodilation in Routine Clinical Practice

> **NCT02675517** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 1737 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Spiolto Respimat

## Key facts

- **NCT ID:** NCT02675517
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-13
- **Primary completion:** 2017-03-10
- **Final completion:** 2017-04-11
- **Target enrollment:** 1737 (ACTUAL)
- **Last updated:** 2018-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02675517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02675517, "Assessment of Physical Functioning and Handling of Spiolto® Respimat® in Patients With Chronic Obstructive Pulmonary Disease (COPD) Requiring Long-acting Dual Bronchodilation in Routine Clinical Practice". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02675517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*